Using Dead Cancer Cells to Activate the Immune System Against Cancer

Billions of aging and damaged cells are eliminated in a controlled manner every day. This process is called apoptosis . A virus-infected cell, meanwhile, is targeted through a mechanism called necroptosis . Necroptosis involves the immune system targeting and destroying the infected cell. Recently, researchers have been investigating how activating necroptosis in cancer cells affects the immune system's ability to produce an anticancer immune response. In this context, a study published in June 2019 in Sciencediscovered that injecting cancer cells undergoing necroptosis (dying cells) into a tumor activates the immune system against cancer . It was also found that using genetic techniques to make cancer cells produce an enzyme that triggers necroptosis increased the effectiveness of immunotherapies .
- Related topic: Two Concepts Closely Related to Cancer: Necrosis and Apoptosis
The study was conducted at the University of Washington in the United States. To examine the effects of necroptotic cells in tumors, researchers used genetic techniques to activate the RIPK3 protein, which triggers the necroptosis pathway in cancer cells. These cells were then injected into mice with melanoma or adenocarcinoma tumors. Analyses during the following week showed slower tumor growth in the mice. This was found to be associated with an increase in killer T cells . The mice injected with cancer cells in which necroptosis had been activated also survived longer. Rather than stimulating T cells to attack the tumor directly, necroptotic cells were found to secrete certain cytokines and chemokines that activated T cells around the tumor.

The researchers also developed another strategy to activate necroptosis. They inserted the gene encoding the necroptosis-activating enzyme (RIPK3) into a virus and delivered it to tumor cells. In this way, the virus would infect cancer cells and make them produce this enzyme. When this method was combined with immunotherapy from the immune checkpoint inhibitor class, tumors were effectively eliminated in mouse models, and no tumor formation was observed in the mice for a long time.
What Does This Study Mean for Us?
- Injecting dying cancer cells into a tumor was found to activate killer T cells against cancer.
- Activating the necroptosis pathway could be an effective cancer treatment strategy. This approach could also improve the effectiveness of immunotherapies.
- Activating necroptosis may be more effective than targeting other cell death pathways. Many tumors can block apoptosis (programmed cell death). Few cancer types develop resistance to necroptosis.
- This study developed 2 methods to activate necroptosis in cancer cells. The first involves activating necroptosis in cancer cells and sending them back to the cells. The second uses viruses to deliver the gene encoding the necroptosis-triggering enzyme into cancer cells so they produce RIPK3. Both methods aim to activate the immune system against cancer through necroptosis.
- It is essential to emphasize that this study is still at the laboratory stage. We do not know what side effects systematically activating the RIPK3 enzyme would cause. Long-term preclinical and clinical studies are needed before this method can be used in clinical practice.
Sources
Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity.
Science Immunology 21 Jun 2019.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.